CALTXS Stock Overview A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Calliditas Therapeutics AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Calliditas Therapeutics Historical stock prices Current Share Price SEK 207.40 52 Week High SEK 208.20 52 Week Low SEK 91.15 Beta 1.46 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change 133.56% 5 Year Change 259.76% Change since IPO 360.89%
Recent News & Updates
Calliditas Therapeutics AB (publ) Announces Board Changes Sep 30 Nasdaq Stockholm Decides to Delist Calliditas Therapeutics Sep 16
Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index Sep 05
Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market Sep 04
Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm Sep 03
Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo Jul 27 See more updates
Calliditas Therapeutics AB (publ) Announces Board Changes Sep 30 Nasdaq Stockholm Decides to Delist Calliditas Therapeutics Sep 16
Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index Sep 05
Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market Sep 04
Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm Sep 03
Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo Jul 27
Calliditas Therapeutics AB Announces Positive Transform Phase 2b Topline Data in Primary Biliary Cholangitis Jul 26
Calliditas Therapeutics AB (publ) Provides Setanaxib Patent Update Jun 20
Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy Jun 01 Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion. May 30
Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and others shareholders for SEK 11.2 billion. May 29
Calliditas Therapeutics AB (Publ) Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 25
Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib May 06
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results Apr 24 Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® Mar 14
Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO Mar 08
Full year 2023 earnings released: kr8.69 loss per share (vs kr7.78 loss in FY 2022) Feb 27
Calliditas Therapeutics AB Provides Patent Update Feb 15 Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023
Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO Dec 21
Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO Dec 11 Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome
Third quarter 2023 earnings released: kr3.14 loss per share (vs kr0.17 loss in 3Q 2022) Nov 09 Nov 08
Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023 Nov 07
Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024 Oct 26
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 Oct 20 Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023 Oct 01
STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization Sep 29
Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024 Aug 24
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy Aug 22
Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy Aug 19 Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023
Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib Jul 14
Independent Chairman recently bought kr1.1m worth of stock Jul 07
Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO Jun 21
Calliditas Therapeutics AB (publ) Announces Board Changes May 31
Forecast breakeven date pushed back to 2024 May 19
Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023 May 16 Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy Feb 03
Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023
Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy Dec 31
Insider recently sold kr532k worth of stock Dec 24
Forecast to breakeven in 2023 Nov 30
Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa Nov 16 Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023
Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy Oct 20
Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023 Aug 18
Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy Jul 16
Calliditas Therapeutics AB Announces Executive Appointments Jul 12 Calliditas Therapeutics AB (Publ) Announces Board Changes
Calliditas Therapeutics AB (Publ) Announces First Patient Randomized in Phase 2 Trial in Head and Neck Cancer May 18
Calliditas Therapeutics AB Launches an Online Patient Platform May 15
Full year 2021 earnings released: kr9.84 loss per share (vs kr9.66 loss in FY 2020) May 03
Forecast breakeven date pushed back to 2024 Feb 26
Calliditas Therapeutics AB (publ) Updates First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib Feb 16
FdA Grants Calliditas Therapeutics Accelerated Approval of Tarpeyo™ (Budesonide) to Reduce Proteinuria in Iga Nephropathy Dec 16
Chief Executive Officer recently bought kr495k worth of stock Nov 24
Forecast to breakeven in 2023 Nov 04
Vice President of Operations recently bought kr88k worth of stock Oct 14
Forecast to breakeven in 2023 Oct 07
Forecast to breakeven in 2023 Sep 23
U.S. Food and Drug Administration Extends Calliditas Therapeutics AB (Publ)'s the PDUFA Goal Date for New Drug Application Sep 15
Calliditas Therapeutics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 324 million. Aug 14
Calliditas Therapeutics AB Receives FDA Fast Track Designation for setanaxib in PBC Aug 09
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency May 29
U.S. Food and Drug Administration Grants Priority Review for Nefecon of Calliditas Therapeutics AB, for Patients with IgA Nephropathy Apr 29
Calliditas Therapeutics AB (publ) Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy Mar 15
Calliditas Therapeutics AB (Publ) Announces Executive Appointments Mar 09
Vice President of Operations recently bought kr121k worth of stock Mar 06
New 90-day low: kr115 Mar 06
Revenue beats expectations Feb 20
Chief Financial Officer recently bought kr385k worth of stock Feb 20 Calliditas Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Apr 27, 2021 Shareholder Returns CALTXS GB Pharmaceuticals GB Market 7D 0% 2.3% 0.3% 1Y n/a -2.3% 6.6%
See full shareholder returns
Return vs Market: Insufficient data to determine how CALTXS performed against the UK Market .
Price Volatility Is CALTXS's price volatile compared to industry and market? CALTXS volatility CALTXS Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: CALTXS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine CALTXS's volatility change over the past year.
About the Company Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Show more Calliditas Therapeutics AB (publ) Fundamentals Summary How do Calliditas Therapeutics's earnings and revenue compare to its market cap? CALTXS fundamental statistics Market cap SEK 11.18b Earnings (TTM ) -SEK 480.36m Revenue (TTM ) SEK 1.60b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CALTXS income statement (TTM ) Revenue SEK 1.60b Cost of Revenue SEK 104.68m Gross Profit SEK 1.50b Other Expenses SEK 1.98b Earnings -SEK 480.36m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
Earnings per share (EPS) -8.89 Gross Margin 93.46% Net Profit Margin -30.00% Debt/Equity Ratio 920.0%
How did CALTXS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/12 02:55 End of Day Share Price 2024/09/10 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Calliditas Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ingird Gafanhão Bryan Garnier & Co Alexandru Cogut Bryan Garnier & Co Erik Hultgård Carnegie Investment Bank AB
Show 7 more analysts 